If you want to step back, yeah, they are mucking up Johnson & Johnson's bid.

In our opinion this news is not new and should not slow down the merger with Guidant.

Interestingly, (Boston Scientific) only raised its bid by $1, signaling that price is but one factor in the negotiation - but includes timeliness of closure.

At this stage in the negotiation process, we believe decisions are being made not only on dollars and cents, but also ego, strategy and a broader view of the competitive landscape.

There's a phrase: to strike while the iron is hot. The iron is hot.

They're certainly making it harder for J&J to come back. Strategically we believe Boston Scientific with Guidant is a better match.

They are playing chicken, and right now it appears that J.& J. has the upper hand.

They are playing chicken, and right now it appears that J&J has the upper hand.

The good news is that this is not a recall, products are not being removed from hospital shelves, and no one has died.

You know where you stand with him. Nothing is candy-coated.